Formation of the immunosuppressive microenvironment of classic Hodgkin lymphoma and therapeutic approaches to counter it
D Aldinucci, C Borghese, N Casagrande - International journal of …, 2019 - mdpi.com
Classic Hodgkin lymphoma (cHL) is characterized by a few tumor cells surrounded by a
protective, immunosuppressive tumor microenvironment composed of normal cells that are …
protective, immunosuppressive tumor microenvironment composed of normal cells that are …
Circadian and immunity cycle talk in cancer destination: from biological aspects to in silico analysis
Simple Summary The circadian cycle is a natural cycle of the body repeated every 24 h,
based on a day and night rhythm, and it affects many body processes. The present article …
based on a day and night rhythm, and it affects many body processes. The present article …
Trabectedin overcomes doxorubicin-resistance, counteracts tumor-immunosuppressive reprogramming of monocytes and decreases xenograft growth in Hodgkin …
N Casagrande, C Borghese, A Favero, C Vicenzetto… - Cancer Letters, 2021 - Elsevier
Classical Hodgkin lymphoma (cHL) tumor cells are surrounded by a protective tumor
microenvironment (TME). Trabectedin, an anticancer drug targeting both tumor cells and …
microenvironment (TME). Trabectedin, an anticancer drug targeting both tumor cells and …
Trabectedin and irinotecan combination regresses a cisplatinum-resistant osteosarcoma in a patient-derived orthotopic xenograft nude-mouse model
Recurrent osteosarcoma is a chemotherapy-resistant disease. Individualized precision
therapy is needed for this disease. Toward this goal, we have developed the patient-derived …
therapy is needed for this disease. Toward this goal, we have developed the patient-derived …
[HTML][HTML] Trabectedin and campthotecin synergistically eliminate cancer stem cells in cell-of-origin sarcoma models
Trabectedin has been approved for second-line treatment of soft tissue sarcomas. However,
its efficacy to target sarcoma initiating cells has not been addressed yet. Here, we used …
its efficacy to target sarcoma initiating cells has not been addressed yet. Here, we used …
In-Silico Identification of Novel Pharmacological Synergisms: The Trabectedin Case
L Mannarino, N Ravasio, M D'Incalci… - International Journal of …, 2024 - mdpi.com
The in-silico strategy of identifying novel uses for already existing drugs, known as drug
repositioning, has enhanced drug discovery. Previous studies have shown a positive …
repositioning, has enhanced drug discovery. Previous studies have shown a positive …
Imidazo[1,2-b]pyrazole-7-carboxamides Induce Apoptosis in Human Leukemia Cells at Nanomolar Concentrations
GJ Szebeni, JA Balog, A Demjén, R Alföldi, VL Végi… - Molecules, 2018 - mdpi.com
Leukemia, the malignancy of the hematopoietic system accounts for 10% of cancer cases
with poor overall survival rate in adults; therefore, there is a high unmet medical need for the …
with poor overall survival rate in adults; therefore, there is a high unmet medical need for the …
Trabectedin is a novel chemotherapy agent for diffuse large B cell lymphoma.
F Spriano, EY Chung, N Panini… - British journal of …, 2019 - search.ebscohost.com
The article discusses a study which hypothesized that trabectedin would be able to displace
the FLI1 oncoprotein and have anti-tumour activity in diffuse large B cell lymphoma …
the FLI1 oncoprotein and have anti-tumour activity in diffuse large B cell lymphoma …